EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)

Preliminary evaluation of a novel PSMA-targeting radiopharmaceutical [68Ga]Ga/[177Lu]Lu–NYM032 for theranostic use in prostate cancer

Haitian Fu, Huihui He, Yanjuan Wang, Wenjin Li, Yihui Luo, Liping Chen, Yuanyuan Mi, Chengwen Sun, Yong Mao, Chunjing Yu iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-024-07046-5 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Haitian Fu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi, Jiangsu Province, 214000, China. Hauptthemen laut MEDLINE: Antigens, Surface, Glutamate Carboxypeptidase II, Lutetium, Prostatic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, SurfaceGlutamate Carboxypeptidase IILutetiumProstatic NeoplasmsRadiopharmaceuticalsTheranostic NanomedicineAgedAnimalsHumansMaleMiceMiddle AgedCell Line, TumorGallium RadioisotopesRadioisotopes

Stichwörter der Autor:innen

NYM032PSMAProstate cancerRadiopharmaceuticalsTheranostics

Substanzen

Antigens, SurfaceFOLH1 protein, humanGallium RadioisotopesGallium-68Glutamate Carboxypeptidase IILutetiumLutetium-177RadioisotopesRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi, Jiangsu Province, 214000, China.
  • Wuxi School of Medicine, Jiangnan University, Wuxi, China.
  • Department of Urological Surgery, Affiliated Hospital of Jiangnan University, Wuxi, China.
  • Wuxi School of Medicine, Jiangnan University, Wuxi, China. mydoctorwx@aliyun.com.
  • Department of Oncology, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi, Jiangsu Province, 214000, China. mydoctorwx@aliyun.com.
  • Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi, Jiangsu Province, 214000, China. ycjwxd1978@jiangnan.edu.cn.

ORCID-Profile: Chunjing Yu

Zitieren

APA

Fu, H., He, H., Wang, Y., Li, W., Luo, Y., Chen, L., Mi, Y., Sun, C., Mao, Y., & Yu, C. (2025). Preliminary evaluation of a novel PSMA-targeting radiopharmaceutical [68Ga]Ga/[177Lu]Lu–NYM032 for theranostic use in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-07046-5

Vancouver

Fu H, He H, Wang Y, Li W, Luo Y, Chen L, et al. Preliminary evaluation of a novel PSMA-targeting radiopharmaceutical [68Ga]Ga/[177Lu]Lu–NYM032 for theranostic use in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-07046-5

BibTeX
@article{Fu2025,
  author = {Fu, Haitian and He, Huihui and Wang, Yanjuan and Li, Wenjin and Luo, Yihui and Chen, Liping and Mi, Yuanyuan and Sun, Chengwen and Mao, Yong and Yu, Chunjing},
  title = {Preliminary evaluation of a novel PSMA-targeting radiopharmaceutical [68Ga]Ga/[177Lu]Lu–NYM032 for theranostic use in prostate cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-024-07046-5}
}
Kostenlos starten →